Efficacy and safety of the combined metabolic medication, containing inosine, nicotinamide, riboflavin and succinic acid, for the treatment of diabetic neuropathy: a multicenter randomized, double-blind, placebo-controlled parallel group clinical trial (CYLINDER).
Tatiana KharitonovaYury G ShvartsAndrey F VerbovoyNatalia S OrlovaValentina P PuzyrevaIgor A StrokovPublished in: BMJ open diabetes research & care (2022)
ClinicalTrials.gov Registry (NCT04649203; Unique Protocol ID: CTF-III-DM-2019).